Cargando…
hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway
Immunocompromised individuals are particularly vulnerable to viral infections and reactivation, especially endogenous herpes viruses such as Epstein-Barr virus (EBV), a member of oncogenic gamma-herpesviruses, which are commonly linked to pneumonia and consequently significant morbidity and mortalit...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499773/ https://www.ncbi.nlm.nih.gov/pubmed/37704783 http://dx.doi.org/10.1186/s43556-023-00137-z |
_version_ | 1785105779876954112 |
---|---|
author | Qin, Aiping Wang, Xiao-juan Fu, Jijun Shen, Ao Huang, Xiaotao Chen, Zhida Wu, Huiting Jiang, Yu Wang, Qian Chen, Fei Xiang, Andy Peng Yu, Xiyong |
author_facet | Qin, Aiping Wang, Xiao-juan Fu, Jijun Shen, Ao Huang, Xiaotao Chen, Zhida Wu, Huiting Jiang, Yu Wang, Qian Chen, Fei Xiang, Andy Peng Yu, Xiyong |
author_sort | Qin, Aiping |
collection | PubMed |
description | Immunocompromised individuals are particularly vulnerable to viral infections and reactivation, especially endogenous herpes viruses such as Epstein-Barr virus (EBV), a member of oncogenic gamma-herpesviruses, which are commonly linked to pneumonia and consequently significant morbidity and mortality. In the study of human and animal oncogenic gammaherpesviruses, the murine gamma-herpesviruses-68 (MHV-68) model has been applied, as it can induce pneumonia in immunocompromised mice. Mesenchymal stem cell (MSC) treatment has demonstrated therapeutic potential for pneumonia, as well as other forms of acute lung injury, in preclinical models. In this study, we aim to investigate the therapeutic efficacy and underlying mechanisms of human bone marrow-derived MSC (hMSC) on MHV-68-induced pneumonia. We found that intravenous administration of hMSCs significantly reduced lung damages, diminished inflammatory mediators and somehow inhibited MHV-68 replication. Furthermore, hMSCs treatment can regulate innate immune response and induce macrophage polarization from M1 to M2 phenotype, could significantly alter leukocyte infiltration and reduce pulmonary fibrosis. Our findings with co-culture system indicated that hMSCs effectively reduced the secretion of of inflammation-related factors and induced a shift in macrophage polarization, consistent with in vivo results. Further investigations revealed that hMSCs treatment suppressed the activation of macrophage ROS/NLRP3 signaling pathway in vivo and in vitro. Moreover, administration of MCC950, a selective NLRP3 inhibitor has been shown to effectively reduce ROS production and subsequently alleviate inflammation induced by MHV-68. Taken together, our work has shown that hMSCs can effectively protect mice from lethal MHV-68 pneumonia, which may throw new light on strategy for combating human EBV-associated pneumonia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-023-00137-z. |
format | Online Article Text |
id | pubmed-10499773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-104997732023-09-15 hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway Qin, Aiping Wang, Xiao-juan Fu, Jijun Shen, Ao Huang, Xiaotao Chen, Zhida Wu, Huiting Jiang, Yu Wang, Qian Chen, Fei Xiang, Andy Peng Yu, Xiyong Mol Biomed Research Immunocompromised individuals are particularly vulnerable to viral infections and reactivation, especially endogenous herpes viruses such as Epstein-Barr virus (EBV), a member of oncogenic gamma-herpesviruses, which are commonly linked to pneumonia and consequently significant morbidity and mortality. In the study of human and animal oncogenic gammaherpesviruses, the murine gamma-herpesviruses-68 (MHV-68) model has been applied, as it can induce pneumonia in immunocompromised mice. Mesenchymal stem cell (MSC) treatment has demonstrated therapeutic potential for pneumonia, as well as other forms of acute lung injury, in preclinical models. In this study, we aim to investigate the therapeutic efficacy and underlying mechanisms of human bone marrow-derived MSC (hMSC) on MHV-68-induced pneumonia. We found that intravenous administration of hMSCs significantly reduced lung damages, diminished inflammatory mediators and somehow inhibited MHV-68 replication. Furthermore, hMSCs treatment can regulate innate immune response and induce macrophage polarization from M1 to M2 phenotype, could significantly alter leukocyte infiltration and reduce pulmonary fibrosis. Our findings with co-culture system indicated that hMSCs effectively reduced the secretion of of inflammation-related factors and induced a shift in macrophage polarization, consistent with in vivo results. Further investigations revealed that hMSCs treatment suppressed the activation of macrophage ROS/NLRP3 signaling pathway in vivo and in vitro. Moreover, administration of MCC950, a selective NLRP3 inhibitor has been shown to effectively reduce ROS production and subsequently alleviate inflammation induced by MHV-68. Taken together, our work has shown that hMSCs can effectively protect mice from lethal MHV-68 pneumonia, which may throw new light on strategy for combating human EBV-associated pneumonia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-023-00137-z. Springer Nature Singapore 2023-09-14 /pmc/articles/PMC10499773/ /pubmed/37704783 http://dx.doi.org/10.1186/s43556-023-00137-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Qin, Aiping Wang, Xiao-juan Fu, Jijun Shen, Ao Huang, Xiaotao Chen, Zhida Wu, Huiting Jiang, Yu Wang, Qian Chen, Fei Xiang, Andy Peng Yu, Xiyong hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway |
title | hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway |
title_full | hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway |
title_fullStr | hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway |
title_full_unstemmed | hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway |
title_short | hMSCs treatment attenuates murine herpesvirus-68 (MHV-68) pneumonia through altering innate immune response via ROS/NLRP3 signaling pathway |
title_sort | hmscs treatment attenuates murine herpesvirus-68 (mhv-68) pneumonia through altering innate immune response via ros/nlrp3 signaling pathway |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499773/ https://www.ncbi.nlm.nih.gov/pubmed/37704783 http://dx.doi.org/10.1186/s43556-023-00137-z |
work_keys_str_mv | AT qinaiping hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT wangxiaojuan hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT fujijun hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT shenao hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT huangxiaotao hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT chenzhida hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT wuhuiting hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT jiangyu hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT wangqian hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT chenfei hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT xiangandypeng hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway AT yuxiyong hmscstreatmentattenuatesmurineherpesvirus68mhv68pneumoniathroughalteringinnateimmuneresponseviarosnlrp3signalingpathway |